![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.055.494![]() |
Chemical and physical data | |
Formula | C21H27N |
Molar mass | 293.454 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Budipine (brand nameParkinsan) is anantiparkinson agent marketed for the treatment ofParkinson's disease.[2][3][4]
While its exactmechanism of action is not well characterized,[2] it is believed to be anNMDA receptor antagonist,[5][6] but also promoting the synthesis ofdopamine.[7]
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[7][8]
It is anhERGblocker and can producelong QT syndrome as aside effect.[9]
Analogues includeprodipine andmedipine.[10][11]
Budipine can be prepared from the 1-tert-butyl-4-piperidone [1465-76-5] directly by treatment with benzene in the presencetriflic acid.[12] This method of synthesis enables a 99% yield of product.
4-Phenyl-1-t-butyl-4-piperidinol,[14] (1)
1-t-butyl-3-benzoyl-4-phenyl-4-piperidinol [81831-81-4] (3)
{{cite book}}
:|journal=
ignored (help)Other representatives of this class of substances, the 1-alkyl-4,4-diphenylpiperidines, such as, e.g., the 1-isopropyl analogue (prodipine) or the 1-methyl analogue (medipine) have similar pharmacological properties including marked tremorin and reserpin antagonism (Schaefer et al., 1984). The mechanism of action of the 1-alkyl-4,4- diphenylpiperidines is not yet understood in detail.
Budipine (1-t-butyl-4,4-diphenylpiperidine) (Parkinson's disease treatment); Prodipine (1-isopropyl-4,4-diphenylpiperidine); Medipine (1-methyl-4,4-diphenylpiperidine)